Literature DB >> 28065736

Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysis.

Thomas H Inge1, Todd M Jenkins2, Stavra A Xanthakos3, John B Dixon4, Stephen R Daniels5, Meg H Zeller6, Michael A Helmrath2.   

Abstract

BACKGROUND: Little is known about the long-term outcomes of bariatric surgery for severe adolescent obesity, raising questions about the durability of early responses to surgery. We aimed to analyse long-term (>5 years) outcomes of Roux-en-Y gastric bypass in a cohort of young adults who had undergone the operation during adolescence, in the Follow-up of Adolescent Bariatric Surgery at 5 Plus Years (FABS-5+) extension study.
METHODS: A cohort of young people aged 13-21 years underwent Roux-en-Y gastric bypass for clinically severe obesity at a paediatric academic medical centre in the USA. We did a prospective follow-up analysis of these patients' outcomes 5-12 years after surgery. Outcomes assessed included BMI, comorbidities, micronutrient status, safety, and other risks. The FABS study is registered with ClinicalTrials.gov, number NCT00776776.
FINDINGS: Between May, 2001, and February, 2007, 74 young people underwent Roux-en-Y gastric bypass in the FABS study. Of these, 58 individuals were eligible for the FABS-5+ study, could be located, and agreed to follow-up assessment. At baseline, the mean age of the cohort was 17·1 years (SD 1·7) and mean BMI was 58·5 kg/m2 (10·5). At mean follow-up of 8·0 years (SD 1·6; range 5·4-12·5), the mean age of the cohort was 25·1 years (2·4) and mean BMI was 41·7 kg/m2 (12·0; mean change in BMI -29·2% [13·7]). From baseline to long-term follow-up, significant declines were recorded in the prevalence of elevated blood pressure (27/57 [47%] vs 9/55 [16%]; p=0·001), dyslipidaemia (48/56 [86%] vs 21/55 [38%]; p<0·0001), and type 2 diabetes (9/56 [16%] vs 1/55 [2%]; p=0·03). At follow-up, 25 (46%) of 58 patients had mild anaemia (ie, not requiring intervention), 22 (45%) had hyperparathyroidism, and eight (16%) had low amounts of vitamin B12 (ie, below the normal cutpoint).
INTERPRETATION: Roux-en-Y gastric bypass surgery resulted in substantial and durable bodyweight reduction and cardiometabolic benefits for young adults. Long-term health maintenance after Roux-en-Y gastric bypass should focus on adherence to dietary supplements and screening and management of micronutrient deficiencies. FUNDING: Ethicon Endosurgery, National Center for Advancing Translational Sciences (US National Institutes of Health).
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28065736     DOI: 10.1016/S2213-8587(16)30315-1

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


  62 in total

1.  Evaluation of the Trends, Characteristics, and Outcomes in North American Youth Undergoing Elective Bariatric Surgery.

Authors:  Valentin Mocanu; Krista Lai; Jerry T Dang; Noah J Switzer; Daniel W Birch; Geoff D C Ball; Shahzeer Karmali
Journal:  Obes Surg       Date:  2021-02-06       Impact factor: 4.129

2.  Cardiovascular Risk Factors After Adolescent Bariatric Surgery.

Authors:  Marc P Michalsky; Thomas H Inge; Todd M Jenkins; Changchun Xie; Anita Courcoulas; Michael Helmrath; Mary L Brandt; Carroll M Harmon; Mike Chen; John B Dixon; Elaine M Urbina
Journal:  Pediatrics       Date:  2018-01-08       Impact factor: 7.124

3.  Obesity: Assessing the long-term outcomes of bariatric surgery in adolescents.

Authors:  Claire Greenhill
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

4.  Nutritional Risks in Adolescents After Bariatric Surgery.

Authors:  Stavra A Xanthakos; Jane C Khoury; Thomas H Inge; Todd M Jenkins; Avani C Modi; Marc P Michalsky; Mike K Chen; Anita P Courcoulas; Carroll M Harmon; Mary L Brandt; Michael A Helmrath; Heidi J Kalkwarf
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-06       Impact factor: 11.382

5.  Heterogeneity in Response to Treatment of Adolescents with Severe Obesity: The Need for Precision Obesity Medicine.

Authors:  Justin R Ryder; Alexander M Kaizer; Todd M Jenkins; Aaron S Kelly; Thomas H Inge; Gabriel Q Shaibi
Journal:  Obesity (Silver Spring)       Date:  2019-02       Impact factor: 5.002

6.  A Multisite 2-Year Follow Up of Psychopathology Prevalence, Predictors, and Correlates Among Adolescents Who Did or Did Not Undergo Weight Loss Surgery.

Authors:  Sanita L Hunsaker; Beth H Garland; Dana Rofey; Jennifer Reiter-Purtill; James Mitchell; Anita Courcoulas; Todd M Jenkins; Meg H Zeller
Journal:  J Adolesc Health       Date:  2018-04-30       Impact factor: 5.012

7.  Impact of Baseline BMI and Adherence to Follow-Up on the Outcome of Sleeve Gastrectomy in Treatment of Adolescent Obesity.

Authors:  Marwan Rasheed Mohammed; Tarek Mahdy; Anas Hashem; Sabah Zaki; Abdulwahid Alwahedi; Hayder Makki; Yaser Asaad; Sameh Hany Emile
Journal:  Obes Surg       Date:  2021-02-23       Impact factor: 4.129

Review 8.  ASMBS pediatric metabolic and bariatric surgery guidelines, 2018.

Authors:  Janey S A Pratt; Allen Browne; Nancy T Browne; Matias Bruzoni; Megan Cohen; Ashish Desai; Thomas Inge; Bradley C Linden; Samer G Mattar; Marc Michalsky; David Podkameni; Kirk W Reichard; Fatima Cody Stanford; Meg H Zeller; Jeffrey Zitsman
Journal:  Surg Obes Relat Dis       Date:  2018-03-23       Impact factor: 4.734

9.  Thirty-Year Risk of Cardiovascular Disease Events in Adolescents with Severe Obesity.

Authors:  Justin R Ryder; Peixin Xu; Thomas H Inge; Changchun Xie; Todd M Jenkins; Chin Hur; Minyi Lee; Jin Choi; Marc P Michalsky; Aaron S Kelly; Elaine M Urbina
Journal:  Obesity (Silver Spring)       Date:  2020-02-05       Impact factor: 5.002

Review 10.  Working toward precision medicine approaches to treat severe obesity in adolescents: report of an NIH workshop.

Authors:  Aaron S Kelly; Marsha D Marcus; Jack A Yanovski; Susan Z Yanovski; Stavroula K Osganian
Journal:  Int J Obes (Lond)       Date:  2018-10-03       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.